Company intelligence / Profile preview
Akan Biosciences
Gaithersburg, Maryland, United Statesakanbio.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Phase 2
01
Overview
StroMel™, their lead candidate for osteoarthritis of the knee, received FDA IND approval in February 2021 and is currently in Phase 2 clinical trials. The company also received a warning letter from the FDA in April 2024 regarding their Ayama™ product, which was being distributed without proper approvals.
- Therapeutic areas
- GastroenterologyPsychiatryRheumatologyDermatologyOther
- Modalities
- Stem cell-based therapeuticsAdipose-derived Stromal Vascular Fraction (SVF)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Akan Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akan Biosciences.